Interventional Oncology Global Market - Forecast To 2029
Interventional Oncology (IO) is a rapidly growing field in cancer care that uses minimally invasive procedures performed under image guidance to diagnose and treat patients with liver, kidney, lung, Brain & Spine, prostate, and other cancers. Rather than removing tumors through open surgical procedures, these image-guided procedures can be performed in place of or in combination with other cancer treatments to provide truly comprehensive care. The advantage of these methods is that IO has much less effect on the body compared to conventional procedures.
According to IQ4I analysis, the interventional oncology global market is expected to grow at a high single from 2022 to 2029. Some of the factors driving the market are the increasing prevalence of cancer cases, the increasing geriatric population and the growing adoption of minimally invasive procedures. Factors such as technological advancements in the field of interventional oncology and expansion in emerging markets are opportunities for the market. Similarly, side effects and risks associated with the use, lack of awareness, and lack of trained professionals are restraining the market growth, While, the availability of alternative treatments and stringent regulatory guidelines are a threat to market growth.
The interventional oncology market is segmented based on products, applications, end-users, and geography. The interventional oncology market based on products is segmented as ablation and embolization. The embolization segment is expected to grow at a mid-single from 2022 to 2029. The ablation segment is the fastest-growing double digit from 2022 to 2029.
Ablation global market based on product type is sub-segmented into radiofrequency ablation, microwave ablation, Cryoablation, HIFU, and others (irreversible electroporation and MRI-guided laser ablation). Among these, microwave ablation is expected to grow at a double-digit from 2022 to 2029. The HIFU segment is the fastest-growing in high teens from 2022. Embolization global market based on procedure is sub-segmented into trans-arterial radioembolization (TARE)/selective internal radiation therapy (SIRT), trans-arterial chemo-embolization (TACE), drug-eluting beads trans-arterial chemo-embolization (DEB-TACE) and trans-arterial embolization (TAE)/bland embolization. Among procedures, TARE/SIRT is expected to grow at a mid-single from 2022 to 2029. The Bland/TAE is the fastest-growing at mid-single from 2022 to 2029.
Interventional oncology global market based on application is segmented into liver cancer, kidney cancer, lung cancer, brain & spine cancer, prostate cancer, and others. Among these applications, the liver cancer segment is expected to grow at mid-single from 2022 to 2029. Brain & spine cancer is the fastest-growing at double-digit from 2022. Further, the application market is sub-segmented into ablation and embolization applications.
The ablation market is segmented into liver cancer, kidney cancer, lung cancer, brain & spine cancer, prostate cancer, and others. Among these applications, the liver cancer segment is expected to grow double-digit from 2022 to 2029. Brain & spine cancer is the fastest-growing segment with a double-digit from 2022 to 2029.
Embolization global market based on application is segmented into liver cancer, lung cancer, prostate cancer, and others. Among embolization applications, the liver cancer segment is expected to grow at mid-single from 2022 to 2029.
The interventional Oncology global market by end-users is segmented into hospitals, ambulatory surgical centers (ASC), and academics & research institutes. Among end-users, the hospital is expected to grow at a high single from 2022 to 2029. The ambulatory surgical center is the fastest-growing at a high single from 2022 to 2029.
The interventional oncology market by region is segmented as North America (U.S. and Rest of North America), Europe (Germany, France, Italy, and Rest of Europe), Asia-Pacific (China, Japan, Australia, and Rest of APAC), and the Rest of the world (Brazil, Rest of LATAM and the Middle East & Others). North America is expected to be at a high single from 2022 to 2029. Mainly due to increasing incidences of cancer, increasing demand for minimally invasive surgeries, favorable reimbursements, product launches, and availability of skilled personnel. The Asia-Pacific is the fastest-growing region with a double-digit from 2022 to 2020. Due to the increasing geriatric population and increasing incidence of cancer, increased expenditure on healthcare facilities, increasing awareness about interventional oncology, and low-cost surgery is driving the market.
The interventional oncology global market is a consolidated market with the top 6 players occupying a major share of the market hence all the existing players in this market are involved in developing new and advanced therapeutics to maintain their market shares. Some of the major players in the interventional oncology market include Medtronic Plc (Ireland), Sirtex Medical (China), Boston Scientific Corporation (U.S.), Angiodynamics (U.S.), Guerbet (France), Merit Medical System (U.S.), Siemens healthineers, Inc. (Varian) (Germany.), Terumo Corporation (Japan), Johnson & Johnson (U.S.), AngioDynamics, Inc. (U.S.), and Monteris Medical (U.S.).
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
According to IQ4I analysis, the interventional oncology global market is expected to grow at a high single from 2022 to 2029. Some of the factors driving the market are the increasing prevalence of cancer cases, the increasing geriatric population and the growing adoption of minimally invasive procedures. Factors such as technological advancements in the field of interventional oncology and expansion in emerging markets are opportunities for the market. Similarly, side effects and risks associated with the use, lack of awareness, and lack of trained professionals are restraining the market growth, While, the availability of alternative treatments and stringent regulatory guidelines are a threat to market growth.
The interventional oncology market is segmented based on products, applications, end-users, and geography. The interventional oncology market based on products is segmented as ablation and embolization. The embolization segment is expected to grow at a mid-single from 2022 to 2029. The ablation segment is the fastest-growing double digit from 2022 to 2029.
Ablation global market based on product type is sub-segmented into radiofrequency ablation, microwave ablation, Cryoablation, HIFU, and others (irreversible electroporation and MRI-guided laser ablation). Among these, microwave ablation is expected to grow at a double-digit from 2022 to 2029. The HIFU segment is the fastest-growing in high teens from 2022. Embolization global market based on procedure is sub-segmented into trans-arterial radioembolization (TARE)/selective internal radiation therapy (SIRT), trans-arterial chemo-embolization (TACE), drug-eluting beads trans-arterial chemo-embolization (DEB-TACE) and trans-arterial embolization (TAE)/bland embolization. Among procedures, TARE/SIRT is expected to grow at a mid-single from 2022 to 2029. The Bland/TAE is the fastest-growing at mid-single from 2022 to 2029.
Interventional oncology global market based on application is segmented into liver cancer, kidney cancer, lung cancer, brain & spine cancer, prostate cancer, and others. Among these applications, the liver cancer segment is expected to grow at mid-single from 2022 to 2029. Brain & spine cancer is the fastest-growing at double-digit from 2022. Further, the application market is sub-segmented into ablation and embolization applications.
The ablation market is segmented into liver cancer, kidney cancer, lung cancer, brain & spine cancer, prostate cancer, and others. Among these applications, the liver cancer segment is expected to grow double-digit from 2022 to 2029. Brain & spine cancer is the fastest-growing segment with a double-digit from 2022 to 2029.
Embolization global market based on application is segmented into liver cancer, lung cancer, prostate cancer, and others. Among embolization applications, the liver cancer segment is expected to grow at mid-single from 2022 to 2029.
The interventional Oncology global market by end-users is segmented into hospitals, ambulatory surgical centers (ASC), and academics & research institutes. Among end-users, the hospital is expected to grow at a high single from 2022 to 2029. The ambulatory surgical center is the fastest-growing at a high single from 2022 to 2029.
The interventional oncology market by region is segmented as North America (U.S. and Rest of North America), Europe (Germany, France, Italy, and Rest of Europe), Asia-Pacific (China, Japan, Australia, and Rest of APAC), and the Rest of the world (Brazil, Rest of LATAM and the Middle East & Others). North America is expected to be at a high single from 2022 to 2029. Mainly due to increasing incidences of cancer, increasing demand for minimally invasive surgeries, favorable reimbursements, product launches, and availability of skilled personnel. The Asia-Pacific is the fastest-growing region with a double-digit from 2022 to 2020. Due to the increasing geriatric population and increasing incidence of cancer, increased expenditure on healthcare facilities, increasing awareness about interventional oncology, and low-cost surgery is driving the market.
The interventional oncology global market is a consolidated market with the top 6 players occupying a major share of the market hence all the existing players in this market are involved in developing new and advanced therapeutics to maintain their market shares. Some of the major players in the interventional oncology market include Medtronic Plc (Ireland), Sirtex Medical (China), Boston Scientific Corporation (U.S.), Angiodynamics (U.S.), Guerbet (France), Merit Medical System (U.S.), Siemens healthineers, Inc. (Varian) (Germany.), Terumo Corporation (Japan), Johnson & Johnson (U.S.), AngioDynamics, Inc. (U.S.), and Monteris Medical (U.S.).
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
- North America
- The U.S.
- Rest of North America
- Europe
- Germany
- France
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- Rest of APAC
- Rest of the World (RoW)
- Brazil
- Rest of LATAM
- The Middle East and Others
1 EXECUTIVE SUMMARY
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 SCOPE OF THE REPORT
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 PRIMARY SOURCES
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Increasing incidence of cancer cases
3.3.1.2 Growing adoption of minimally invasive procedures
3.3.1.3 Increasing geriatric population
3.3.1.4 Technological advancements in the field of interventional oncology
3.3.1.5 Expansion in the emerging markets
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 Side effects and risks associated with the use
3.3.2.2 Lack of awareness
3.3.2.3 Lack of trained professionals
3.3.2.4 Availability of alternative treatments
3.3.2.5 Stringent regulatory guidelines
3.4 REGULATORY AFFAIRS
3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
3.4.1.1 ISO 9001: 2015 Quality Management System
3.4.1.2 ISO:13485 Medical Devices
3.4.1.3 ISO 10993 Biological Evaluation Of Medical Devices
3.4.1.4 ISO 14971 Risk Management Of Medical Devices
3.4.1.5 ISO 12807:2018 Safe Transport of Radioactive Materials- Leakage Testing on Packages
3.4.1.6 IEC 60601-1 Medical Electrical Equipment Standard
3.4.1.7 IEC 60601-1-2 Electromagnetic Compatibility (EMC) for Medical Devices
3.4.2 U.S.
3.4.3 CANADA
3.4.4 EUROPE
3.4.5 JAPAN
3.4.6 CHINA
3.4.7 INDIA
3.5 CLINICAL TRIALS DATA
3.6 PORTER’S FIVE FORCE ANALYSIS
3.6.1 THREAT OF NEW ENTRANTS
3.6.2 THREAT OF SUBSTITUTES
3.6.3 BARGAINING POWER OF SUPPLIERS
3.6.4 BARGAINING POWER OF BUYERS
3.6.5 COMPETITIVE RIVALRY
3.7 SUPPLY CHAIN ANALYSIS
3.8 FUNDING SCENARIO
3.9 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.9.1 INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE ANALYSIS
3.9.2 IO ABLATION GLOBAL MARKET SHARE ANALYSIS
3.9.3 IO EMBOLIZATION GLOBAL MARKET SHARE ANALYSIS
3.9.4 RADIOFREQUENCY ABLATION GLOBAL MARKET SHARE ANALYSIS
3.9.5 IO MICROWAVE ABLATION GLOBAL MARKET SHARE ANALYSIS
3.9.6 IO TARE GLOBAL MARKET SHARE ANALYSIS
3.9.7 IO DEB-TACE GLOBAL MARKET SHARE ANALYSIS
3.9.8 IO TAE GLOBAL MARKET SHARE ANALYSIS
3.10 INTERVENTIONAL ONCOLOGY PROCEDURE VOLUME, BASED ON PRODUCT TYPE
3.10.1 IO ABLATION DEVICES UNITS PER PROCEDURE, AVERAGE SELLING PRICE, NUMBER OF PROCEDURES AND UNITS SOLD
3.10.2 IO EMBOLIZATION UNITS PER PROCEDURE, AVERAGE SELLING PRICE AND NUMBER OF PROCEDURES
3.11 INTERVENTIONAL ONCOLOGY NUMBER OF UNITS BASED ON REGION
3.11.1 IO ABLATION DEVICES NUMBER OF UNITS BASED ON REGION
3.11.2 IO RADIOFREQUENCY ABLATION DEVICES NUMBER OF UNITS, BASED ON REGION
3.11.3 IO MICROWAVE ABLATION DEVICES NUMBER OF UNITS, BASED ON REGION
3.11.4 IO CRYOABLATION DEVICES NUMBER OF UNITS BASED ON REGION
3.11.5 ANALYSIS OF INTERVENTION ONCOLOGY ABLATION DEVICES BY UNIT VOLUME BASED ON COUNTRY (NOS)
4 INTERVENTIONAL ONCOLOGY GLOBAL MARKET, BASED ON PRODUCT
4.1 INTRODUCTION
4.2 ABLATION
4.2.1 RADIOFREQUENCY ABLATION
4.2.2 MICROWAVE ABLATION
4.2.3 CRYOABLATION
4.2.4 HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU)
4.2.5 OTHER ABLATION
4.3 EMBOLIZATION
4.3.1 IO TRANS-ARTERIAL RADIO-EMBOLIZATION(TARE)/SELECTIVE INTERNAL RADIATION THERAPY (SIRT)
4.3.2 IO TRANSARTERIAL CHEMO-EMBOLIZATION (TACE)
4.3.3 IO DRUG-ELUTING BEADS TRANSARTERIAL CHEMO-EMBOLIZATION (DEB-TACE)
4.3.4 IO BLAND EMBOLIZATION/ TRANSARTERIAL EMBOLIZATION (TAE)
5 INTERVENTIONAL ONCOLOGY GLOBAL MARKET, BASED ON APPLICATION
5.1 INTRODUCTION
5.1.1 LIVER CANCER
5.1.2 KIDNEY CANCER
5.1.3 LUNG CANCER
5.1.4 BRAIN AND SPINE CANCER
5.1.5 PROSTATE CANCER
5.1.6 OTHER APPLICATIONS
6 INTERVENTIONAL ONCOLOGY GLOBAL MARKET, BASED ON END-USERS
6.1 INTRODUCTION
6.1.1 HOSPITALS
6.1.2 AMBULATORY SURGICAL CENTERS (ASCS)
6.1.3 ACADEMICS AND RESEARCH INSTITUTES
7 REGIONAL ANALYSIS
7.1 INTRODUCTION
7.2 NORTH AMERICA
7.2.1 U.S.
7.2.2 REST OF NORTH AMERICA
7.3 EUROPE
7.3.1 GERMANY
7.3.2 FRANCE
7.3.3 ITALY
7.3.4 REST OF E.U.
7.4 APAC
7.4.1 CHINA
7.4.2 JAPAN
7.4.3 AUSTRALIA
7.4.4 REST OF APAC
7.5 ROW
7.5.1 BRAZIL
7.5.2 REST OF LATAM
7.5.3 MIDDLE EAST AND OTHERS
8 MAJOR COMPANIES
8.1 ANGIODYNAMICS INC.
8.1.1 OVERVIEW
8.1.2 FINANCIALS
8.1.3 PRODUCT PORTFOLIO
8.1.4 KEY DEVELOPMENTS
8.1.5 BUSINESS STRATEGY
8.1.6 SWOT ANALYSIS
8.2 BOSTON SCIENTIFIC CORPORATION
8.2.1 OVERVIEW
8.2.2 FINANCIALS
8.2.3 PRODUCT PORTFOLIO
8.2.4 KEY DEVELOPMENTS
8.2.5 BUSINESS STRATEGY
8.2.6 SWOT ANALYSIS
8.3 CDH INVESTMENTS (CDH GENTECH LTD), (SIRTEX LTD.)
8.3.1 OVERVIEW
8.3.2 FINANCIALS
8.3.3 PRODUCT PORTFOLIO
8.3.4 KEY DEVELOPMENTS
8.3.5 BUSINESS STRATEGY
8.3.6 SWOT ANALYSIS
8.4 GUERBET
8.4.1 OVERVIEW
8.4.2 FINANCIALS
8.4.3 PRODUCT PORTFOLIO
8.4.4 KEY DEVELOPMENTS
8.4.5 BUSINESS STRATEGY
8.4.6 SWOT ANALYSIS
8.5 JOHNSON & JOHNSON
8.5.1 OVERVIEW
8.5.2 FINANCIALS
8.5.3 PRODUCT PORTFOLIO
8.5.4 KEY DEVELOPMENTS
8.5.5 BUSINESS STRATEGY
8.5.6 SWOT ANALYSIS
8.6 MEDTRONIC, PLC
8.6.1 OVERVIEW
8.6.2 FINANCIALS
8.6.3 PRODUCT PORTFOLIO
8.6.4 KEY DEVELOPMENTS
8.6.5 BUSINESS STRATEGY
8.6.6 SWOT ANALYSIS
8.7 MERIT MEDICAL SYSTEMS, INC
8.7.1 OVERVIEW
8.7.2 FINANCIALS
8.7.3 PRODUCT PORTFOLIO
8.7.4 KEY DEVELOPMENTS
8.7.5 BUSINESS STRATEGY
8.7.6 SWOT ANALYSIS
8.8 MONTERIS MEDICAL
8.8.1 OVERVIEW
8.8.2 FINANCIALS
8.8.3 PRODUCT PORTFOLIO
8.8.4 KEY DEVELOPMENTS
8.8.5 BUSINESS STRATEGY
8.8.6 SWOT ANALYSIS
8.9 SIEMENS HEALTHINEERS (VARIAN MEDICAL)
8.9.1 OVERVIEW
8.9.2 FINANCIALS
8.9.3 PRODUCT PORTFOLIO
8.9.4 KEY DEVELOPMENTS
8.9.5 BUSINESS STRATEGY
8.9.6 SWOT ANALYSIS
8.10 TERUMO CORPORATION
8.10.1 OVERVIEW
8.10.2 FINANCIALS
8.10.3 PRODUCT PORTFOLIO
8.10.4 KEY DEVELOPMENTS
8.10.5 BUSINESS STRATEGY
8.10.6 SWOT ANALYSIS
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 SCOPE OF THE REPORT
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 PRIMARY SOURCES
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Increasing incidence of cancer cases
3.3.1.2 Growing adoption of minimally invasive procedures
3.3.1.3 Increasing geriatric population
3.3.1.4 Technological advancements in the field of interventional oncology
3.3.1.5 Expansion in the emerging markets
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 Side effects and risks associated with the use
3.3.2.2 Lack of awareness
3.3.2.3 Lack of trained professionals
3.3.2.4 Availability of alternative treatments
3.3.2.5 Stringent regulatory guidelines
3.4 REGULATORY AFFAIRS
3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
3.4.1.1 ISO 9001: 2015 Quality Management System
3.4.1.2 ISO:13485 Medical Devices
3.4.1.3 ISO 10993 Biological Evaluation Of Medical Devices
3.4.1.4 ISO 14971 Risk Management Of Medical Devices
3.4.1.5 ISO 12807:2018 Safe Transport of Radioactive Materials- Leakage Testing on Packages
3.4.1.6 IEC 60601-1 Medical Electrical Equipment Standard
3.4.1.7 IEC 60601-1-2 Electromagnetic Compatibility (EMC) for Medical Devices
3.4.2 U.S.
3.4.3 CANADA
3.4.4 EUROPE
3.4.5 JAPAN
3.4.6 CHINA
3.4.7 INDIA
3.5 CLINICAL TRIALS DATA
3.6 PORTER’S FIVE FORCE ANALYSIS
3.6.1 THREAT OF NEW ENTRANTS
3.6.2 THREAT OF SUBSTITUTES
3.6.3 BARGAINING POWER OF SUPPLIERS
3.6.4 BARGAINING POWER OF BUYERS
3.6.5 COMPETITIVE RIVALRY
3.7 SUPPLY CHAIN ANALYSIS
3.8 FUNDING SCENARIO
3.9 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.9.1 INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE ANALYSIS
3.9.2 IO ABLATION GLOBAL MARKET SHARE ANALYSIS
3.9.3 IO EMBOLIZATION GLOBAL MARKET SHARE ANALYSIS
3.9.4 RADIOFREQUENCY ABLATION GLOBAL MARKET SHARE ANALYSIS
3.9.5 IO MICROWAVE ABLATION GLOBAL MARKET SHARE ANALYSIS
3.9.6 IO TARE GLOBAL MARKET SHARE ANALYSIS
3.9.7 IO DEB-TACE GLOBAL MARKET SHARE ANALYSIS
3.9.8 IO TAE GLOBAL MARKET SHARE ANALYSIS
3.10 INTERVENTIONAL ONCOLOGY PROCEDURE VOLUME, BASED ON PRODUCT TYPE
3.10.1 IO ABLATION DEVICES UNITS PER PROCEDURE, AVERAGE SELLING PRICE, NUMBER OF PROCEDURES AND UNITS SOLD
3.10.2 IO EMBOLIZATION UNITS PER PROCEDURE, AVERAGE SELLING PRICE AND NUMBER OF PROCEDURES
3.11 INTERVENTIONAL ONCOLOGY NUMBER OF UNITS BASED ON REGION
3.11.1 IO ABLATION DEVICES NUMBER OF UNITS BASED ON REGION
3.11.2 IO RADIOFREQUENCY ABLATION DEVICES NUMBER OF UNITS, BASED ON REGION
3.11.3 IO MICROWAVE ABLATION DEVICES NUMBER OF UNITS, BASED ON REGION
3.11.4 IO CRYOABLATION DEVICES NUMBER OF UNITS BASED ON REGION
3.11.5 ANALYSIS OF INTERVENTION ONCOLOGY ABLATION DEVICES BY UNIT VOLUME BASED ON COUNTRY (NOS)
4 INTERVENTIONAL ONCOLOGY GLOBAL MARKET, BASED ON PRODUCT
4.1 INTRODUCTION
4.2 ABLATION
4.2.1 RADIOFREQUENCY ABLATION
4.2.2 MICROWAVE ABLATION
4.2.3 CRYOABLATION
4.2.4 HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU)
4.2.5 OTHER ABLATION
4.3 EMBOLIZATION
4.3.1 IO TRANS-ARTERIAL RADIO-EMBOLIZATION(TARE)/SELECTIVE INTERNAL RADIATION THERAPY (SIRT)
4.3.2 IO TRANSARTERIAL CHEMO-EMBOLIZATION (TACE)
4.3.3 IO DRUG-ELUTING BEADS TRANSARTERIAL CHEMO-EMBOLIZATION (DEB-TACE)
4.3.4 IO BLAND EMBOLIZATION/ TRANSARTERIAL EMBOLIZATION (TAE)
5 INTERVENTIONAL ONCOLOGY GLOBAL MARKET, BASED ON APPLICATION
5.1 INTRODUCTION
5.1.1 LIVER CANCER
5.1.2 KIDNEY CANCER
5.1.3 LUNG CANCER
5.1.4 BRAIN AND SPINE CANCER
5.1.5 PROSTATE CANCER
5.1.6 OTHER APPLICATIONS
6 INTERVENTIONAL ONCOLOGY GLOBAL MARKET, BASED ON END-USERS
6.1 INTRODUCTION
6.1.1 HOSPITALS
6.1.2 AMBULATORY SURGICAL CENTERS (ASCS)
6.1.3 ACADEMICS AND RESEARCH INSTITUTES
7 REGIONAL ANALYSIS
7.1 INTRODUCTION
7.2 NORTH AMERICA
7.2.1 U.S.
7.2.2 REST OF NORTH AMERICA
7.3 EUROPE
7.3.1 GERMANY
7.3.2 FRANCE
7.3.3 ITALY
7.3.4 REST OF E.U.
7.4 APAC
7.4.1 CHINA
7.4.2 JAPAN
7.4.3 AUSTRALIA
7.4.4 REST OF APAC
7.5 ROW
7.5.1 BRAZIL
7.5.2 REST OF LATAM
7.5.3 MIDDLE EAST AND OTHERS
8 MAJOR COMPANIES
8.1 ANGIODYNAMICS INC.
8.1.1 OVERVIEW
8.1.2 FINANCIALS
8.1.3 PRODUCT PORTFOLIO
8.1.4 KEY DEVELOPMENTS
8.1.5 BUSINESS STRATEGY
8.1.6 SWOT ANALYSIS
8.2 BOSTON SCIENTIFIC CORPORATION
8.2.1 OVERVIEW
8.2.2 FINANCIALS
8.2.3 PRODUCT PORTFOLIO
8.2.4 KEY DEVELOPMENTS
8.2.5 BUSINESS STRATEGY
8.2.6 SWOT ANALYSIS
8.3 CDH INVESTMENTS (CDH GENTECH LTD), (SIRTEX LTD.)
8.3.1 OVERVIEW
8.3.2 FINANCIALS
8.3.3 PRODUCT PORTFOLIO
8.3.4 KEY DEVELOPMENTS
8.3.5 BUSINESS STRATEGY
8.3.6 SWOT ANALYSIS
8.4 GUERBET
8.4.1 OVERVIEW
8.4.2 FINANCIALS
8.4.3 PRODUCT PORTFOLIO
8.4.4 KEY DEVELOPMENTS
8.4.5 BUSINESS STRATEGY
8.4.6 SWOT ANALYSIS
8.5 JOHNSON & JOHNSON
8.5.1 OVERVIEW
8.5.2 FINANCIALS
8.5.3 PRODUCT PORTFOLIO
8.5.4 KEY DEVELOPMENTS
8.5.5 BUSINESS STRATEGY
8.5.6 SWOT ANALYSIS
8.6 MEDTRONIC, PLC
8.6.1 OVERVIEW
8.6.2 FINANCIALS
8.6.3 PRODUCT PORTFOLIO
8.6.4 KEY DEVELOPMENTS
8.6.5 BUSINESS STRATEGY
8.6.6 SWOT ANALYSIS
8.7 MERIT MEDICAL SYSTEMS, INC
8.7.1 OVERVIEW
8.7.2 FINANCIALS
8.7.3 PRODUCT PORTFOLIO
8.7.4 KEY DEVELOPMENTS
8.7.5 BUSINESS STRATEGY
8.7.6 SWOT ANALYSIS
8.8 MONTERIS MEDICAL
8.8.1 OVERVIEW
8.8.2 FINANCIALS
8.8.3 PRODUCT PORTFOLIO
8.8.4 KEY DEVELOPMENTS
8.8.5 BUSINESS STRATEGY
8.8.6 SWOT ANALYSIS
8.9 SIEMENS HEALTHINEERS (VARIAN MEDICAL)
8.9.1 OVERVIEW
8.9.2 FINANCIALS
8.9.3 PRODUCT PORTFOLIO
8.9.4 KEY DEVELOPMENTS
8.9.5 BUSINESS STRATEGY
8.9.6 SWOT ANALYSIS
8.10 TERUMO CORPORATION
8.10.1 OVERVIEW
8.10.2 FINANCIALS
8.10.3 PRODUCT PORTFOLIO
8.10.4 KEY DEVELOPMENTS
8.10.5 BUSINESS STRATEGY
8.10.6 SWOT ANALYSIS
LIST OF TABLES
TABLE 1 INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 2 IO ABLATION GLOBAL PROCEDURE VOLUME, BASED ON PRODUCT TYPE, (2021-2029) (NOS)
TABLE 3 ANALYSIS OF IO ABLATION DEVICES FOR PROCEDURAL VOLUME BASED ON COUNTRY (NOS)
TABLE 4 IO ABLATION DEVICES UNITS PER PROCEDURE, AVERAGE SELLING PRICE, NUMBER OF PROCEDURES AND UNITS SOLD, BASED ON REGION, (2022) (NOS.)
TABLE 5 IO EMBOLIZATION GLOBAL PROCEDURE VOLUME, BASED ON PRODUCT TYPE, (2021-2029) (NO’S)
TABLE 6 IO EMBOLIZATION DEVICES UNITS PER PROCEDURE, AVERAGE SELLING PRICE AND NUMBER OF PROCEDURES, BASED ON REGION, (2022) (NOS)
TABLE 7 IO ABLATION DEVICES NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NOS)
TABLE 8 IO ABLATION DEVICES NUMBER OF UNITS, BASED ON PRODUCTS, (2021-2029) (NOS)
TABLE 9 RADIOFREQUENCY ABLATION DEVICES NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NOS)
TABLE 10 IO MICROWAVE ABLATION DEVICES NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NOS)
TABLE 11 IO CRYOABLATION DEVICES NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NOS)
TABLE 12 INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
TABLE 13 IO ABLATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 14 IO ABLATION GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
TABLE 15 IO RADIOFREQUENCY ABLATION GLOBAL MARKET REVENUE, BAESD ON REGION, (2021-2029) ($MN)
TABLE 16 IO MICROWAVE ABLATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 17 IO CRYOABLATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 18 IO HIFU ABLATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 19 IO OTHER ABLATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 20 IO EMBOLIZATION GLOBAL MARKET REVENUE, BASED ON REGION, 2021-2029) ($MN)
TABLE 21 IO EMBOLIZATION GLOBAL MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
TABLE 22 IO TARE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 23 IO TACE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 24 IO DEB-TACE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 25 IO BLAND/TAE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 26 TAE AND DEB-TACE PRODUCTS MATRIX
TABLE 27 INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BASED ON APPLICATION (2021-2029) ($MN)
TABLE 28 IO ABLATION GLOBAL MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 29 IO EMBOLIZATION GLOBAL MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 30 IO LIVER CANCER APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 31 IO LIVER CANCER ABLATION APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 32 IO LIVER CANCER EMBOLIZATION APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 33 IO KIDNEY CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 34 IO LUNG CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 35 IO LUNG CANCER ABLATION APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 36 IO LUNG CANCER EMBOLIZATION APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 37 IO BRAIN & SPINE CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 38 IO PROSTATE CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 39 IO PROSTATE CANCER ABLATION APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 40 IO PROSTATE CANCER EMBOLIZATION APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 41 IO OTHER APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 42 IO OTHER ABLATION APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 43 IO OTHER EMBOLIZATON APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 44 INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
TABLE 45 IO HOSPITALS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 46 IO AMBULATORY SURGICAL CENTERS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 47 IO ACADEMICS AND RESEARCH INSTITUTES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 48 INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 49 NORTH AMERICA IO MARKET REVENUE, BASED ON PRODUCTS, (2021-2029) ($MN)
TABLE 50 NORTH AMERICA IO ABLATION MARKET REVENUE, BASED ON PRODUCT TYPE , (2021-2029) ($MN)
TABLE 51 NORTH AMERICA IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
TABLE 52 NORTH AMERICA IO MARKET REVENUE, BASED ON APPLICATION (2021-2029) ($MN)
TABLE 53 NORTH AMERICA IO ABLATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 54 NORTH AMERICA IO EMBOLIZATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 55 NORTH AMERICA IO MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
TABLE 56 NORTH AMERICA IO MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
TABLE 57 EUROPE IO MARKET REVENUE, BASED ON PRODUCTS, (2021-2029) ($MN)
TABLE 58 EUROPE IO ABLATION MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
TABLE 59 EUROPE IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
TABLE 60 EUROPE IO MARKET REVENUE, BASED ON APPLICATION (2021-2029) ($MN)
TABLE 61 EUROPE IO ABLATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 62 EUROPE IO EMBOLIZATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 63 EUROPE IO MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
TABLE 64 EUROPE IO MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
TABLE 65 APAC IO MARKET REVENUE, BASED ON PRODUCT (2021-2029) ($MN)
TABLE 66 APAC IO ABLATION MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
TABLE 67 APAC IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
TABLE 68 APAC IO MARKET REVENUE, BASED ON APPLICATION (2021-2029) ($MN)
TABLE 69 APAC IO ABLATION MARKET REVENUE, BASED ON APPLICATION (2021-2029) ($MN)
TABLE 70 APAC IO EMBOLIZATION MARKET REVENUE, BASED ON APPLICATION (2021-2029) ($MN)
TABLE 71 APAC IO MARKET REVENUE, BASED ON END USERS (2021-2029) ($MN)
TABLE 72 APAC IO MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
TABLE 73 ROW IO MARKET REVENUE, BASED ON PRODUCT (2021-2029) ($MN)
TABLE 74 ROW IO ABLATION MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
TABLE 75 ROW IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
TABLE 76 ROW IO MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 77 ROW IO ABLATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 78 ROW IO EMBOLIZATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 79 ROW IO MARKET REVENUE, BASED ON END-USERS (2021-2029) ($MN)
TABLE 80 ROW IO MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
TABLE 81 ANGIODYNAMICS, INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) ($MN)
TABLE 82 ANGIODYNAMICS, INC.: TOTAL REVENUE, BY SEGMENT, (2020-2022) ($MN)
TABLE 83 ANGIODYNAMICS, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) ($MN)
TABLE 84 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q1) ($MN)
TABLE 85 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q1) ($MN)
TABLE 86 BOSTON SCIENTIFIC CORP.: CARDIOVASCULAR TOTAL REVENUE, BASED ON SUB-SEGMENT, (2020-2022)(Q1) ($MN)
TABLE 87 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) (Q1) ($MN)
TABLE 88 GUERBET: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2) ($MN)
TABLE 89 GUERBET: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022) (Q2) ($MN)
TABLE 90 GUERBET: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q2) ($MN)
TABLE 91 JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2)($MN)
TABLE 92 JOHNSON & JOHNSON: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q2) ($MN)
TABLE 93 JOHNSON & JOHNSON: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q2) ($MN)
TABLE 94 MEDTRONIC, PLC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) ($MN)
TABLE 95 MEDTRONIC, PLC: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) ($MN)
TABLE 96 MEDTRONIC, PLC: CARDIOVASCULAR TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022) ($MN)
TABLE 97 MEDTRONIC, PLC: NEUROSCIENCES TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022) ($MN)
TABLE 98 MEDTRONIC, PLC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) ($MN)
TABLE 99 MERIT MEDICAL SYSTEMS, INC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q1) ($MN)
TABLE 100 MERIT MEDICAL SYSTEMS, INC: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q1) ($MN)
TABLE 101 MERIT MEDICAL SYSTEMS, INC: CARDIOVASCULAR TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022)(Q1) ($MN)
TABLE 102 MERIT MEDICAL SYSTEMS, INC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022)(Q1) ($MN)
TABLE 103 SIEMENS HEALTHINEERS MEDICAL SYSTEM INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q2) ($MN)
TABLE 104 SIEMENS HEALTHINEERS MEDICAL SYSTEM INC.: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022)(Q2) ($MN)
TABLE 105 SIEMENS HEALTHINEERS MEDICAL SYSTEM INC.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022)(Q2) ($MN)
TABLE 106 TERUMO CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) ($MN)
TABLE 107 TERUMO CORPORATION: TOTAL REVENUE, BASED ON SEGMENT, (2019-2021) ($MN)
TABLE 108 TERUMO CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY, (2019-2021) ($MN)
TABLE 1 INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 2 IO ABLATION GLOBAL PROCEDURE VOLUME, BASED ON PRODUCT TYPE, (2021-2029) (NOS)
TABLE 3 ANALYSIS OF IO ABLATION DEVICES FOR PROCEDURAL VOLUME BASED ON COUNTRY (NOS)
TABLE 4 IO ABLATION DEVICES UNITS PER PROCEDURE, AVERAGE SELLING PRICE, NUMBER OF PROCEDURES AND UNITS SOLD, BASED ON REGION, (2022) (NOS.)
TABLE 5 IO EMBOLIZATION GLOBAL PROCEDURE VOLUME, BASED ON PRODUCT TYPE, (2021-2029) (NO’S)
TABLE 6 IO EMBOLIZATION DEVICES UNITS PER PROCEDURE, AVERAGE SELLING PRICE AND NUMBER OF PROCEDURES, BASED ON REGION, (2022) (NOS)
TABLE 7 IO ABLATION DEVICES NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NOS)
TABLE 8 IO ABLATION DEVICES NUMBER OF UNITS, BASED ON PRODUCTS, (2021-2029) (NOS)
TABLE 9 RADIOFREQUENCY ABLATION DEVICES NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NOS)
TABLE 10 IO MICROWAVE ABLATION DEVICES NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NOS)
TABLE 11 IO CRYOABLATION DEVICES NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NOS)
TABLE 12 INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
TABLE 13 IO ABLATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 14 IO ABLATION GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
TABLE 15 IO RADIOFREQUENCY ABLATION GLOBAL MARKET REVENUE, BAESD ON REGION, (2021-2029) ($MN)
TABLE 16 IO MICROWAVE ABLATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 17 IO CRYOABLATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 18 IO HIFU ABLATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 19 IO OTHER ABLATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 20 IO EMBOLIZATION GLOBAL MARKET REVENUE, BASED ON REGION, 2021-2029) ($MN)
TABLE 21 IO EMBOLIZATION GLOBAL MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
TABLE 22 IO TARE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 23 IO TACE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 24 IO DEB-TACE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 25 IO BLAND/TAE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 26 TAE AND DEB-TACE PRODUCTS MATRIX
TABLE 27 INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BASED ON APPLICATION (2021-2029) ($MN)
TABLE 28 IO ABLATION GLOBAL MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 29 IO EMBOLIZATION GLOBAL MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 30 IO LIVER CANCER APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 31 IO LIVER CANCER ABLATION APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 32 IO LIVER CANCER EMBOLIZATION APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 33 IO KIDNEY CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 34 IO LUNG CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 35 IO LUNG CANCER ABLATION APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 36 IO LUNG CANCER EMBOLIZATION APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 37 IO BRAIN & SPINE CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 38 IO PROSTATE CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 39 IO PROSTATE CANCER ABLATION APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 40 IO PROSTATE CANCER EMBOLIZATION APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 41 IO OTHER APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 42 IO OTHER ABLATION APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 43 IO OTHER EMBOLIZATON APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 44 INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
TABLE 45 IO HOSPITALS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 46 IO AMBULATORY SURGICAL CENTERS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 47 IO ACADEMICS AND RESEARCH INSTITUTES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 48 INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 49 NORTH AMERICA IO MARKET REVENUE, BASED ON PRODUCTS, (2021-2029) ($MN)
TABLE 50 NORTH AMERICA IO ABLATION MARKET REVENUE, BASED ON PRODUCT TYPE , (2021-2029) ($MN)
TABLE 51 NORTH AMERICA IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
TABLE 52 NORTH AMERICA IO MARKET REVENUE, BASED ON APPLICATION (2021-2029) ($MN)
TABLE 53 NORTH AMERICA IO ABLATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 54 NORTH AMERICA IO EMBOLIZATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 55 NORTH AMERICA IO MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
TABLE 56 NORTH AMERICA IO MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
TABLE 57 EUROPE IO MARKET REVENUE, BASED ON PRODUCTS, (2021-2029) ($MN)
TABLE 58 EUROPE IO ABLATION MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
TABLE 59 EUROPE IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
TABLE 60 EUROPE IO MARKET REVENUE, BASED ON APPLICATION (2021-2029) ($MN)
TABLE 61 EUROPE IO ABLATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 62 EUROPE IO EMBOLIZATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 63 EUROPE IO MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
TABLE 64 EUROPE IO MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
TABLE 65 APAC IO MARKET REVENUE, BASED ON PRODUCT (2021-2029) ($MN)
TABLE 66 APAC IO ABLATION MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
TABLE 67 APAC IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
TABLE 68 APAC IO MARKET REVENUE, BASED ON APPLICATION (2021-2029) ($MN)
TABLE 69 APAC IO ABLATION MARKET REVENUE, BASED ON APPLICATION (2021-2029) ($MN)
TABLE 70 APAC IO EMBOLIZATION MARKET REVENUE, BASED ON APPLICATION (2021-2029) ($MN)
TABLE 71 APAC IO MARKET REVENUE, BASED ON END USERS (2021-2029) ($MN)
TABLE 72 APAC IO MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
TABLE 73 ROW IO MARKET REVENUE, BASED ON PRODUCT (2021-2029) ($MN)
TABLE 74 ROW IO ABLATION MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
TABLE 75 ROW IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
TABLE 76 ROW IO MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 77 ROW IO ABLATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 78 ROW IO EMBOLIZATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 79 ROW IO MARKET REVENUE, BASED ON END-USERS (2021-2029) ($MN)
TABLE 80 ROW IO MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
TABLE 81 ANGIODYNAMICS, INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) ($MN)
TABLE 82 ANGIODYNAMICS, INC.: TOTAL REVENUE, BY SEGMENT, (2020-2022) ($MN)
TABLE 83 ANGIODYNAMICS, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) ($MN)
TABLE 84 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q1) ($MN)
TABLE 85 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q1) ($MN)
TABLE 86 BOSTON SCIENTIFIC CORP.: CARDIOVASCULAR TOTAL REVENUE, BASED ON SUB-SEGMENT, (2020-2022)(Q1) ($MN)
TABLE 87 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) (Q1) ($MN)
TABLE 88 GUERBET: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2) ($MN)
TABLE 89 GUERBET: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022) (Q2) ($MN)
TABLE 90 GUERBET: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q2) ($MN)
TABLE 91 JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2)($MN)
TABLE 92 JOHNSON & JOHNSON: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q2) ($MN)
TABLE 93 JOHNSON & JOHNSON: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q2) ($MN)
TABLE 94 MEDTRONIC, PLC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) ($MN)
TABLE 95 MEDTRONIC, PLC: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) ($MN)
TABLE 96 MEDTRONIC, PLC: CARDIOVASCULAR TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022) ($MN)
TABLE 97 MEDTRONIC, PLC: NEUROSCIENCES TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022) ($MN)
TABLE 98 MEDTRONIC, PLC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) ($MN)
TABLE 99 MERIT MEDICAL SYSTEMS, INC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q1) ($MN)
TABLE 100 MERIT MEDICAL SYSTEMS, INC: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q1) ($MN)
TABLE 101 MERIT MEDICAL SYSTEMS, INC: CARDIOVASCULAR TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022)(Q1) ($MN)
TABLE 102 MERIT MEDICAL SYSTEMS, INC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022)(Q1) ($MN)
TABLE 103 SIEMENS HEALTHINEERS MEDICAL SYSTEM INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q2) ($MN)
TABLE 104 SIEMENS HEALTHINEERS MEDICAL SYSTEM INC.: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022)(Q2) ($MN)
TABLE 105 SIEMENS HEALTHINEERS MEDICAL SYSTEM INC.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022)(Q2) ($MN)
TABLE 106 TERUMO CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) ($MN)
TABLE 107 TERUMO CORPORATION: TOTAL REVENUE, BASED ON SEGMENT, (2019-2021) ($MN)
TABLE 108 TERUMO CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY, (2019-2021) ($MN)
LIST OF FIGURES
FIGURE 1 INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
FIGURE 2 RESEARCH METHODOLOGY: INTERVENTIONAL ONCOLOGY GLOBAL MARKET
FIGURE 3 INTERVENTIONAL ONCOLOGY GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 INTERVENTIONAL ONCOLOGY GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 INTERVENTIONAL ONCOLOGY GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 INTERVENTIONAL ONCOLOGY GLOBAL MARKET SEGMENTATION
FIGURE 7 INTERVENTIONAL ONCOLOGY APPLICATION MARKET SEGMENTATION
FIGURE 8 MARKET DYNAMICS
FIGURE 9 INTERVENTIONAL ONCOLOGY GLOBAL MARKET: PORTER’S ANALYSIS
FIGURE 10 INTERVENTIONAL ONCOLOGY: SUPPLY CHAIN ANALYSIS
FIGURE 11 INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS 2022 (%)
FIGURE 12 IO ABLATION GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
FIGURE 13 IO EMBOLIZATION GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2022 (%)
FIGURE 14 IO RADIOFREQUENCY ABLATION GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
FIGURE 15 IO MICROWAVE ABLATION GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
FIGURE 16 IO TARE GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
FIGURE 17 IO DEB-TACE GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
FIGURE 18 IO TAE GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
FIGURE 19 IO ABLATION GLOBAL PROCEDURE VOLUME, BASED ON PRODUCT TYPE, (2021-2029) (NOS)
FIGURE 20 IO EMBOLIZATION GLOBAL PROCEDURE VOLUME, BASED ON PRODUCT TYPE, (2021-2029) (NOS)
FIGURE 21 IO ABLATION DEVICES NUMBER OF UNITS, BASED ON PRODUCT, (2021-2029) (NOS)
FIGURE 22 IO RADIOFREQUENCY ABLATION DEVICES NUMBER OF UNITS, BASED ON REGION (2022) (NOS)
FIGURE 23 IO MICROWAVE ABLATION DEVICES NUMBER OF UNITS, BASED ON REGION (2022) (NOS)
FIGURE 24 IO CRYOABLATION DEVICES NUMBER OF UNITS, BASED ON REGION (2022) (NOS)
FIGURE 25 INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
FIGURE 26 IO ABLATION GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
FIGURE 27 IO CRYOABLATION GLOBAL MARKET SHARE, BASED ON REGION (2022 V/S 2029) (%)
FIGURE 28 IO HIFU ABLATION GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
FIGURE 29 IO EMBOLIZATION GLOBAL MARKET SHARE, BASED ON PROCEDURE (2022 VS 2029) (%)
FIGURE 30 IO DEB-TACE GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
FIGURE 31 IO BLAND/TAE GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
FIGURE 32 INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE, BASED ON APPLICATION (2022 VS 2029) (%)
FIGURE 33 IO ABLATION GLOBAL MARKET SHARE, BASED ON APPLICATION (2022) (%)
FIGURE 34 IO EMBOLIZATION GLOBAL MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
FIGURE 35 IO PROSTATE CANCER ABLATION APPLICATION GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
FIGURE 36 INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE, BASED ON END-USERS (2022 V/S 2029) (%)
FIGURE 37 IO HOSPITALS GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
FIGURE 38 IO GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN), CAGR (%)
FIGURE 39 IO GLOBAL MARKET SHARE, BASED ON REGION AND MARKET REVENUE BASED ON COUNTRY (2022) (%) ($MN)
FIGURE 40 NORTH AMERICA IO MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 41 NORTH AMERICA IO ABLATION MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
FIGURE 42 NORTH AMERICA IO EMBOLIZATION MARKET SHARE, BASED ON PROCEDURE (2022 V/S 2029) (%)
FIGURE 43 NORTH AMERICA IO MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
FIGURE 44 NORTH AMERICA IO ABLATION MARKET SHARE, BASED ON APPLICATION (2022) (%)
FIGURE 45 NORTH AMERICA IO EMBOLIZATION MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
FIGURE 46 NORTH AMERICA IO MARKET SHARE, BASED ON END-USERS (2022 V/S 2029) (%)
FIGURE 47 NORTH AMERICA IO MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
FIGURE 48 U.S. IO MARKET REVENUE, BASED ON PRODUCTS AND END USERS (2022 V/S 2029) ($MN)
FIGURE 49 U.S. IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 50 U.S. IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 51 REST OF N.A. IO MARKET REVENUE BASED ON PRODUCTS & END USER (2022 VS 2029) ($MN)
FIGURE 52 REST OF N.A. IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 53 REST OF N.A. IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 54 EUROPE IO MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 55 EUROPE IO MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
FIGURE 56 EUROPE IO EMBOLIZATION MARKET SHARE, BASED ON PROCEDURE (2022 V/S 2029) (%)
FIGURE 57 EUROPE IO MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
FIGURE 58 EUROPE IO ABLATION MARKET SHARE, BASED ON APPLICATION (2022) (%)
FIGURE 59 EUROPE IO EMBOLIZATION MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
FIGURE 60 EUROPE IO MARKET SHARE, BASED ON END-USERS (2022 V/S 2029) (%)
FIGURE 61 EUROPE IO MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
FIGURE 62 GERMANY IO MARKET REVENUE, BASED ON PRODUCTS & END-USER (2022 VS 2029) ($MN)
FIGURE 63 GERMANY IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 64 GERMANY IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE & APPLICATION (2022 VS 2029) ($MN)
FIGURE 65 FRANCE IO MARKET REVENUE, BASED ON PRODUCTS & END-USER (2022 VS 2029) ($MN)
FIGURE 66 FRANCE IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 67 FRANCE IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 68 ITALY IO MARKET REVENUE, BASED ON PRODUCTS & END-USER (2022 VS 2029) ($MN)
FIGURE 69 ITALY IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 70 ITALY IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 71 REST OF E.U. IO MARKET REVENUE, BASED ON PRODUCTS & END-USER (2022 VS 2029) ($MN)
FIGURE 72 REST OF E.U. IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 73 REST OF E.U. IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 74 APAC IO MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
FIGURE 75 APAC IO ABLATION MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
FIGURE 76 APAC IO EMBOLIZATION MARKET SHARE, BASED ON PROCEDURE (2022 V/S 2029) (%)
FIGURE 77 APAC IO MARKET SHARE, BASED ON APPLICATION (2022 VS 2029) (%)
FIGURE 78 APAC IO ABLATION MARKET SHARE, BASED ON APPLICATION (2022) (%)
FIGURE 79 APAC IO EMBOLIZATION MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
FIGURE 80 APAC IO MARKET SHARE, BASED ON END USERS (2022 V/S 2029) (%)
FIGURE 81 APAC IO MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
FIGURE 82 CHINA IO MARKET REVENUE, BASED ON PRODUCTS & END-USER (2022 VS 2029) ($MN)
FIGURE 83 CHINA IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 84 CHINA IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 85 JAPAN IO MARKET REVENUE, BASED ON PRODUCTS & END-USER (2022 VS 2029) ($MN)
FIGURE 86 JAPAN IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 V/S 2029) (%)
FIGURE 87 JAPAN IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 88 AUSTRALIA IO MARKET REVENUE, BASED ON PRODUCTS & END-USERS (2022 VS 2029) ($MN)
FIGURE 89 AUSTRALIA IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 90 AUSTRALIA IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 91 REST OF APAC IO MARKET REVENUE BASED ON PRODUCTS & END-USERS (2022 VS 2029) ($MN)
FIGURE 92 REST OF APAC IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 93 REST OF APAC IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 94 ROW IO MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 95 ROW IO ABLATION MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)
FIGURE 96 ROW IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE, (2022 VS 2029) (%)
FIGURE 97 ROW IO MARKET SHARE, BASED ON APPLICATION (2022) (%) (% CAGR)
FIGURE 98 ROW IO ABLATION MARKET SHARE, BASED ON APPLICATION (2022) (%) (% CAGR)
FIGURE 99 ROW IO EMBOLIZATION MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
FIGURE 100 ROW IO MARKET SHARE, BASED ON END-USERS (2022 VS 2029) (%)
FIGURE 101 ROW IO MARKET SHARE, BASED ON COUNTRY (2022 VS 2029) (%)
FIGURE 102 BRAZIL IO MARKET REVENUE, BASED ON PRODUCTS & END-USERS (2022VS 2029) ($MN)
FIGURE 103 BRAZIL IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 104 BRAZIL IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 105 REST OF LATAM IO MARKET REVENUE, BASED ON PRODUCTS & END-USERS (2022 VS 2029) ($MN)
FIGURE 106 REST OF LATAM IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 107 REST OF LATAM IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 108 MIDDLE EAST & OTHERS IO MARKET REVENUE, BASED ON PRODUCTS & END-USERS (2022 VS 2029) ($MN)
FIGURE 109 MIDDLE EAST & OTHERS IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 110 MIDDLE EAST & OTHERS IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 111 SWOT: ANGIODYNAMICS, INC.
FIGURE 112 SWOT: BOSTON SCIENTIFIC CORPORATION
FIGURE 113 SWOT: CDH INVESTMENTS
FIGURE 114 SWOT: GUERBET
FIGURE 115 SWOT: JOHNSON & JOHNSON
FIGURE 116 SWOT: MEDTRONIC, PLC
FIGURE 117 SWOT: MERIT MEDICAL SYSTEMS, INC.
FIGURE 118 SWOT: MONTERIS MEDICAL
FIGURE 119 SWOT: SIEMENS HEALTHINEERS MEDICAL SYSTEM INC.
FIGURE 120 SWOT: TERUMO CORPORATION
FIGURE 1 INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
FIGURE 2 RESEARCH METHODOLOGY: INTERVENTIONAL ONCOLOGY GLOBAL MARKET
FIGURE 3 INTERVENTIONAL ONCOLOGY GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 INTERVENTIONAL ONCOLOGY GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 INTERVENTIONAL ONCOLOGY GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 INTERVENTIONAL ONCOLOGY GLOBAL MARKET SEGMENTATION
FIGURE 7 INTERVENTIONAL ONCOLOGY APPLICATION MARKET SEGMENTATION
FIGURE 8 MARKET DYNAMICS
FIGURE 9 INTERVENTIONAL ONCOLOGY GLOBAL MARKET: PORTER’S ANALYSIS
FIGURE 10 INTERVENTIONAL ONCOLOGY: SUPPLY CHAIN ANALYSIS
FIGURE 11 INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS 2022 (%)
FIGURE 12 IO ABLATION GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
FIGURE 13 IO EMBOLIZATION GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2022 (%)
FIGURE 14 IO RADIOFREQUENCY ABLATION GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
FIGURE 15 IO MICROWAVE ABLATION GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
FIGURE 16 IO TARE GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
FIGURE 17 IO DEB-TACE GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
FIGURE 18 IO TAE GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
FIGURE 19 IO ABLATION GLOBAL PROCEDURE VOLUME, BASED ON PRODUCT TYPE, (2021-2029) (NOS)
FIGURE 20 IO EMBOLIZATION GLOBAL PROCEDURE VOLUME, BASED ON PRODUCT TYPE, (2021-2029) (NOS)
FIGURE 21 IO ABLATION DEVICES NUMBER OF UNITS, BASED ON PRODUCT, (2021-2029) (NOS)
FIGURE 22 IO RADIOFREQUENCY ABLATION DEVICES NUMBER OF UNITS, BASED ON REGION (2022) (NOS)
FIGURE 23 IO MICROWAVE ABLATION DEVICES NUMBER OF UNITS, BASED ON REGION (2022) (NOS)
FIGURE 24 IO CRYOABLATION DEVICES NUMBER OF UNITS, BASED ON REGION (2022) (NOS)
FIGURE 25 INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
FIGURE 26 IO ABLATION GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
FIGURE 27 IO CRYOABLATION GLOBAL MARKET SHARE, BASED ON REGION (2022 V/S 2029) (%)
FIGURE 28 IO HIFU ABLATION GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
FIGURE 29 IO EMBOLIZATION GLOBAL MARKET SHARE, BASED ON PROCEDURE (2022 VS 2029) (%)
FIGURE 30 IO DEB-TACE GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
FIGURE 31 IO BLAND/TAE GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
FIGURE 32 INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE, BASED ON APPLICATION (2022 VS 2029) (%)
FIGURE 33 IO ABLATION GLOBAL MARKET SHARE, BASED ON APPLICATION (2022) (%)
FIGURE 34 IO EMBOLIZATION GLOBAL MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
FIGURE 35 IO PROSTATE CANCER ABLATION APPLICATION GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
FIGURE 36 INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE, BASED ON END-USERS (2022 V/S 2029) (%)
FIGURE 37 IO HOSPITALS GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
FIGURE 38 IO GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN), CAGR (%)
FIGURE 39 IO GLOBAL MARKET SHARE, BASED ON REGION AND MARKET REVENUE BASED ON COUNTRY (2022) (%) ($MN)
FIGURE 40 NORTH AMERICA IO MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 41 NORTH AMERICA IO ABLATION MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
FIGURE 42 NORTH AMERICA IO EMBOLIZATION MARKET SHARE, BASED ON PROCEDURE (2022 V/S 2029) (%)
FIGURE 43 NORTH AMERICA IO MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
FIGURE 44 NORTH AMERICA IO ABLATION MARKET SHARE, BASED ON APPLICATION (2022) (%)
FIGURE 45 NORTH AMERICA IO EMBOLIZATION MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
FIGURE 46 NORTH AMERICA IO MARKET SHARE, BASED ON END-USERS (2022 V/S 2029) (%)
FIGURE 47 NORTH AMERICA IO MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
FIGURE 48 U.S. IO MARKET REVENUE, BASED ON PRODUCTS AND END USERS (2022 V/S 2029) ($MN)
FIGURE 49 U.S. IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 50 U.S. IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 51 REST OF N.A. IO MARKET REVENUE BASED ON PRODUCTS & END USER (2022 VS 2029) ($MN)
FIGURE 52 REST OF N.A. IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 53 REST OF N.A. IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 54 EUROPE IO MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 55 EUROPE IO MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
FIGURE 56 EUROPE IO EMBOLIZATION MARKET SHARE, BASED ON PROCEDURE (2022 V/S 2029) (%)
FIGURE 57 EUROPE IO MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
FIGURE 58 EUROPE IO ABLATION MARKET SHARE, BASED ON APPLICATION (2022) (%)
FIGURE 59 EUROPE IO EMBOLIZATION MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
FIGURE 60 EUROPE IO MARKET SHARE, BASED ON END-USERS (2022 V/S 2029) (%)
FIGURE 61 EUROPE IO MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
FIGURE 62 GERMANY IO MARKET REVENUE, BASED ON PRODUCTS & END-USER (2022 VS 2029) ($MN)
FIGURE 63 GERMANY IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 64 GERMANY IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE & APPLICATION (2022 VS 2029) ($MN)
FIGURE 65 FRANCE IO MARKET REVENUE, BASED ON PRODUCTS & END-USER (2022 VS 2029) ($MN)
FIGURE 66 FRANCE IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 67 FRANCE IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 68 ITALY IO MARKET REVENUE, BASED ON PRODUCTS & END-USER (2022 VS 2029) ($MN)
FIGURE 69 ITALY IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 70 ITALY IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 71 REST OF E.U. IO MARKET REVENUE, BASED ON PRODUCTS & END-USER (2022 VS 2029) ($MN)
FIGURE 72 REST OF E.U. IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 73 REST OF E.U. IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 74 APAC IO MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
FIGURE 75 APAC IO ABLATION MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
FIGURE 76 APAC IO EMBOLIZATION MARKET SHARE, BASED ON PROCEDURE (2022 V/S 2029) (%)
FIGURE 77 APAC IO MARKET SHARE, BASED ON APPLICATION (2022 VS 2029) (%)
FIGURE 78 APAC IO ABLATION MARKET SHARE, BASED ON APPLICATION (2022) (%)
FIGURE 79 APAC IO EMBOLIZATION MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
FIGURE 80 APAC IO MARKET SHARE, BASED ON END USERS (2022 V/S 2029) (%)
FIGURE 81 APAC IO MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
FIGURE 82 CHINA IO MARKET REVENUE, BASED ON PRODUCTS & END-USER (2022 VS 2029) ($MN)
FIGURE 83 CHINA IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 84 CHINA IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 85 JAPAN IO MARKET REVENUE, BASED ON PRODUCTS & END-USER (2022 VS 2029) ($MN)
FIGURE 86 JAPAN IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 V/S 2029) (%)
FIGURE 87 JAPAN IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 88 AUSTRALIA IO MARKET REVENUE, BASED ON PRODUCTS & END-USERS (2022 VS 2029) ($MN)
FIGURE 89 AUSTRALIA IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 90 AUSTRALIA IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 91 REST OF APAC IO MARKET REVENUE BASED ON PRODUCTS & END-USERS (2022 VS 2029) ($MN)
FIGURE 92 REST OF APAC IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 93 REST OF APAC IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 94 ROW IO MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 95 ROW IO ABLATION MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)
FIGURE 96 ROW IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE, (2022 VS 2029) (%)
FIGURE 97 ROW IO MARKET SHARE, BASED ON APPLICATION (2022) (%) (% CAGR)
FIGURE 98 ROW IO ABLATION MARKET SHARE, BASED ON APPLICATION (2022) (%) (% CAGR)
FIGURE 99 ROW IO EMBOLIZATION MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
FIGURE 100 ROW IO MARKET SHARE, BASED ON END-USERS (2022 VS 2029) (%)
FIGURE 101 ROW IO MARKET SHARE, BASED ON COUNTRY (2022 VS 2029) (%)
FIGURE 102 BRAZIL IO MARKET REVENUE, BASED ON PRODUCTS & END-USERS (2022VS 2029) ($MN)
FIGURE 103 BRAZIL IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 104 BRAZIL IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 105 REST OF LATAM IO MARKET REVENUE, BASED ON PRODUCTS & END-USERS (2022 VS 2029) ($MN)
FIGURE 106 REST OF LATAM IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 107 REST OF LATAM IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 108 MIDDLE EAST & OTHERS IO MARKET REVENUE, BASED ON PRODUCTS & END-USERS (2022 VS 2029) ($MN)
FIGURE 109 MIDDLE EAST & OTHERS IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 110 MIDDLE EAST & OTHERS IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
FIGURE 111 SWOT: ANGIODYNAMICS, INC.
FIGURE 112 SWOT: BOSTON SCIENTIFIC CORPORATION
FIGURE 113 SWOT: CDH INVESTMENTS
FIGURE 114 SWOT: GUERBET
FIGURE 115 SWOT: JOHNSON & JOHNSON
FIGURE 116 SWOT: MEDTRONIC, PLC
FIGURE 117 SWOT: MERIT MEDICAL SYSTEMS, INC.
FIGURE 118 SWOT: MONTERIS MEDICAL
FIGURE 119 SWOT: SIEMENS HEALTHINEERS MEDICAL SYSTEM INC.
FIGURE 120 SWOT: TERUMO CORPORATION
